Literature DB >> 24718847

The changing paradigm for supportive care in cancer patients.

Alexandre Chan1, Jude Lees, Dorothy Keefe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24718847     DOI： 10.1007/s00520-014-2229-9

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


× No keyword cloud information.
  20 in total

1.  Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.

Authors:  Victor Huang; Donna Hepper; Milan Anadkat; Lynn Cornelius
Journal:  Arch Dermatol       Date:  2012-05

Review 2.  Tumor control versus adverse events with targeted anticancer therapies.

Authors:  Dorothy M K Keefe; Emma H Bateman
Journal:  Nat Rev Clin Oncol       Date:  2011-12-20       Impact factor: 66.675

Review 3.  Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma.

Authors:  L Albiges; F Chamming's; B Duclos; M Stern; R J Motzer; A Ravaud; P Camus
Journal:  Ann Oncol       Date:  2012-06-11       Impact factor: 32.976

4.  Pharmacogenetic analysis of BR.21, a placebo-controlled randomized phase III clinical trial of erlotinib in advanced non-small cell lung cancer.

Authors:  Geoffrey Liu; D Cheng; K Ding; A Le Maitre; N Liu; D Patel; Z Chen; L Seymour; F A Shepherd; M S Tsao
Journal:  J Thorac Oncol       Date:  2012-02       Impact factor: 15.609

Review 5.  Mammalian target of rapamycin inhibitor-associated stomatitis.

Authors:  Christine B Boers-Doets; Judith E Raber-Durlacher; Nathaniel S Treister; Joel B Epstein; Anniek B P Arends; Diede R Wiersma; Rajesh V Lalla; Richard M Logan; Nielka P van Erp; Hans Gelderblom
Journal:  Future Oncol       Date:  2013-12       Impact factor: 3.404

6.  Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.

Authors:  Yi Ling Teo; Xue Jing Chong; Xiu Ping Chue; Noan Minh Chau; Min-Han Tan; Ravindran Kanesvaran; Hwee Lin Wee; Han Kiat Ho; Alexandre Chan
Journal:  Cancer Chemother Pharmacol       Date:  2013-12-04       Impact factor: 3.333

7.  The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.

Authors:  Beatrice Nardone; Jennifer R Hensley; Laura Kulik; Dennis P West; Mary Mulcahy; Alfred Rademaker; Mario E Lacouture
Journal:  J Drugs Dermatol       Date:  2012-11       Impact factor: 2.114

8.  Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden.

Authors:  Alexandre Chan; Yu Yan Chiang; Xiu Hui Low; Kevin Yi-Lwern Yap; Raymond Ng
Journal:  Support Care Cancer       Date:  2013-08-22       Impact factor: 3.603

Review 9.  Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.

Authors:  Mario E Lacouture; Milan J Anadkat; René-Jean Bensadoun; Jane Bryce; Alexandre Chan; Joel B Epstein; Beth Eaby-Sandy; Barbara A Murphy
Journal:  Support Care Cancer       Date:  2011-06-01       Impact factor: 3.603

Review 10.  Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Hong-bing Liu; Ying Wu; Tang-feng Lv; Yan-wen Yao; Yong-ying Xiao; Dong-mei Yuan; Yong Song
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240
View more
  2 in total

1.  NICSO: Network Italiano Cure di Supporto in Oncologia--Italian Network for Supportive Care in Oncology.

Authors:  Fausto Roila; Carla Ida Ripamonti; Andrea Antonuzzo; Paolo Bossi
Journal:  Support Care Cancer       Date:  2014-10-16       Impact factor: 3.603

2.  Dealing with death in cancer care: should the oncologist be an amicus mortis?

Authors:  D Carrieri; F A Peccatori; L Grassi; G Boniolo
Journal:  Support Care Cancer       Date:  2019-11-12       Impact factor: 3.603
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.